Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial by Heijde, D. van der et al.
  699van der Heijde D, et al. Ann Rheum Dis 2018;77:699–705. doi:10.1136/annrheumdis-2017-212377
Clinical and epidemiological research
ExtEndEd rEport
Limited radiographic progression and sustained 
reductions in MRI inflammation in patients with axial 
spondyloarthritis: 4-year imaging outcomes from the 
RAPID-axSpA phase III randomised trial
désirée van der Heijde,1 xenofon Baraliakos,2 Kay-Geert A Hermann,3 
robert B M Landewé,4 pedro M Machado,5 Walter p Maksymowych,6 owen r davies,7 
natasha de peyrecave,7 Bengt Hoepken,8 Lars Bauer,8 tommi nurminen,8 
Juergen Braun9
AbstrACt
Objectives to report 4-year imaging outcomes 
in the rApId-axSpA (nCt01087762) study of 
patients with ankylosing spondylitis (AS) and non-
radiographic axial spondyloarthritis (nr-axSpA), 
treated with certolizumab pegol (CZp).
Methods this phase III, randomised trial was 
placebo-controlled and double-blind to week 24, 
dose-blind to week 48 and open-label to week 204. 
patients fulfilling the Assessment of Spondyloarthritis 
International Society (ASAS) axSpA criteria with 
active disease were stratified (AS/nr-axSpA) 
according to the modified new York (mnY) criteria 
at randomisation. Spinal radiographs were assessed 
using the modified Stoke Ankylosing Spondylitis 
Spine Score (mSASSS). MrI inflammation used the 
Spondyloarthritis research Consortium of Canada 
(SpArCC) score for sacroiliac joints (SIJ) and the 
Berlin spinal score (remission defined as SpArCC 
<2 and Berlin ≤2, respectively).
results MrI improvements from baseline (BL) to 
week 12 were maintained to week 204 (SpArCC BL: 
AS=8.5, nr-axSpA=7.5; SpArCC week 204: AS=1.3, 
nr-axSpA=2.4; Berlin BL: AS=7.4, nr-axSpA=4.4; 
Berlin week 204: AS=2.6, nr-axSpA=1.9). 66.7% 
of patients with AS and 69.6% of patients with 
nr-axSpA with BL SpArCC scores ≥2, and 65.4% 
of patients with AS and 57.3% of patients with nr-
axSpA with BL Berlin score >2, achieved remission 
at week 204. Mean mSASSS change in AS from BL 
to week 204 was 0.98 (95% CI 0.34, 1.63); 0.67 
(95% CI 0.21,1.13) from BL to week 96; and 0.31 
(95% CI 0.02,0.60) from week 96 to week 204. 
Corresponding nr-axSpA changes were 0.06 (95% CI 
−0.17,0.28), –0.01 (95% CI −0.19,0.17) and 0.07 
(95% CI −0.07,0.20). 4.5% of patients with nr-
axSpA fulfilled the mnY criteria at week 204, while 
4.3% of patients with AS no longer did so.
Conclusions In patients with CZp-treated axSpA, 
rapid decreases in spinal and SIJ MrI inflammation 
were maintained to week 204. overall, 4-year spinal 
progression was low, with less progression during 
years 2–4 than 0–2. radiographic SIJ grading 
changes demonstrated limited progression.
trial registration number nCt01087762; post-
results.
IntrOduCtIOn
Axial spondyloarthritis (axSpA) is a chronic inflamma-
tory disease primarily characterised by inflammation 
of the axial skeleton (the spine and the sacroiliac (SI) 
joints). Patients with evidence of structural damage to 
the SI joints (radiographic sacroiliitis), which is iden-
tifiable using X-ray imaging and fulfils the modified 
New York (mNY) classification criteria, are consid-
ered to have ankylosing spondylitis (AS; also termed 
radiographic axSpA). However, many patients with 
axSpA do not fulfil the mNY criteria; this is termed 
non-radiographic axSpA (nr-axSpA) and has the 
potential to develop into AS.1 2 Importantly, the 
disease burden and clinical features are similar in both 
subpopulations, representing a spectrum of the same 
disease.3 4 
In contrast to clinical outcomes, long-term imaging 
data in tumour necrosis factor (TNF) inhibitor-treated 
patients are limited. There are currently no long-term 
modified Stoke Ankylosing Spondylitis Spine Score 
(mSASSS)5 data available for patients with nr-axSpA.
RAPID-axSpA is the only large trial to include 
both patients with AS and nr-axSpA and previ-
ously demonstrated that certolizumab pegol (CZP), 
a PEGylated fragment-crystallisable (Fc)-free 
anti-TNF agent, improved the signs and symptoms 
of axSpA from as early as 12 weeks of treatment, 
which were maintained over 4 years.4 6–8
Here, we report the imaging outcomes over 4 years 
of CZP treatment. This represents the longest term 
MRI imaging study in patients with anti-TNF-treated 
axSpA to date, and the only data addressing X-ray and 




RAPID-axSpA (NCT01087762) was a 204-week, 
phase III, randomised, parallel-group, multicentre 
trial, conducted at 83 centres in Europe, North 
America and Latin America. The study was place-
bo-controlled and double-blind until week 24, dose-
blind to week 48 and open-label to week 204.
Full details have been published previ-
ously.4 Patients were randomised 1:1:1 to placebo 
or CZP 400 mg at weeks 0, 2 and 4 (loading dose), 
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followed by either CZP 200 mg every 2 weeks or CZP 400 mg 
every 4 weeks (online supplementary figure 1).
Patients
Full inclusion and exclusion criteria have been reported previ-
ously.4 Eligible participants were aged ≥18 years at screening 
and fulfilled the ASAS axSpA classification criteria, with a clinical 
diagnosis of adult-onset axSpA of ≥3 months’ duration and active 
disease defined by Bath Ankylosing Spondylitis Activity Index 
≥4, spinal pain ≥4 on a 0–10 Numerical Rating Scale, and either 
elevated C-reactive protein (>7.9 mg/L) or a positive SI joint MRI 
assessment.
To define AS and nr-axSpA subpopulations, the most recent 
SI joint X-rays (performed ≤12 months prior to screening) were 
locally read to determine the presence/absence of radiographic 
sacroiliitis.
study procedures and evaluations
The primary outcome (ASAS20 response at week 12) has been 
reported previously,4 as have clinical data to week 2046 7 and 
imaging data to week 96.4 6 8–10 Here we report the long-term 
imaging results (radiographs and MRI of both SI joints and 
spine) from the complete 4-year study period.
SI joint X-rays were conducted at baseline and week 204/early 
withdrawal (if after week 104). Lateral radiographs of the lumbar/
cervical spine were performed at baseline, week 96 and week 204. 
MRI assessments of both the spine and SI joints were conducted 
at baseline and weeks 12, 48, 96 and 204. MRI and radiograph 
assessments were each performed independently by two central 
readers blinded to timepoint, treatment group and clinical data. In 
the event of disagreement between central readers when grading 
SI joint radiographs, an additional third reader assessed the radio-
graphs from the patient in question. A third reader was not used 
for MRI or spinal radiographs.
The short tau inversion recovery sequence of MRI scans was 
assessed for disease activity using the Spondyloarthritis Research 
Consortium of Canada (SPARCC) scoring method for SI joints 
(0–72 scale)11 and the Berlin modification of the Ankylosing 
Spondylitis spine MRI-activity scoring system for the spine (0–69 
scale).12 Spinal radiographs were assessed using the mSASSS 
scoring method.
Data are reported from the week 204 reading campaign, 
which included all available images from baseline to week 204 
with the exception of SI joint radiographs; only SI joint images 
from patients with both baseline and week 204/early withdrawal 
radiographs were included.
statistical analysis
Data are presented for patients who received ≥1 dose of CZP 
(200 mg every 2 weeks (Q2W) and 400 mg every 4 weeks (Q4W) 
groups combined) at any timepoint to week 204, including 
rerandomised placebo-treated patients. Statistical analyses were 
conducted assuming data were missing at random.13 The number 
of images available for each imaging modality is presented 
in online supplementary table 1.
The MRI set included all randomised patients with valid MRI 
assessments (either spine or SI joint) at baseline and ≥1 other 
timepoint during the trial (n=158). Week 12 MRI data were not 
used from patients randomised to placebo. Average MRI scores 
of the two readers were considered for statistical analyses, and 
group least squares (LS) mean Berlin and SPARCC scores were 
estimated post hoc by mixed-model repeated measures (MMRM) 
analysis on observed data using ‘visit’ as a fixed factor with an 
unstructured within-patient covariance matrix. The propor-
tions achieving MRI remission (SPARCC <2 or Berlin ≤2) 
were estimated by multiple imputation: estimated proportions 
of patients in MRI remission were pooled from 50 multiply 
imputed data sets, where missing actual scores were imputed 
via predicted mean matching, with the predicted value at a visit 
based on linear regression of values from other visits.14 15 Results 
were summarised for patients with MRI baseline inflammation 
(Berlin score >2 or SPARCC score ≥2).
Radiographic data were examined for all CZP-treated patients 
with ≥1 mSASSS assessment (X-ray set), including those reran-
domised from placebo. Based on average scores of the two 
readers, LS mean mSASSS and changes between visits were esti-
mated using MMRM analyses on observed data, as described 
above. The online supplementary material includes observed 
mean changes for subjects with a complete sequence of images at 
baseline, week 96 and week 204. Radiographic progression rates 
(an increase of ≥2 points from baseline) at weeks 96 and 204 
were estimated using multiple imputation, as described above. 
Within-patient correlation coefficients were calculated between 
change from baseline to week 96, and change from week 96 to 
week 204. Plausibility of the missing-at-random assumption was 
evaluated by comparing disease activity outcomes of patients 
with no mSASSS data at week 96/week 204 and those with data 
at all relevant timepoints. In particular, Ankylosing Spondylitis 
Disease Activity Score (ASDAS) levels were compared using 
observed data and last observation carried forward-imputed 
data. For plots of individual patient mSASSS results, observed 
data are presented for all patients with ≥2 valid mSASSS assess-
ments. Patients with ≥1 non-bridging or bridging syndesmophyte 
(defined as a score of 2 or 3, respectively) and syndesmophyte 
formation (defined as a shift in score from 0 or 1 to 2 or 3) were 
considered when reported by both readers for a given vertebral 
edge.
Presence of definitive sacroiliitis (grade ≥2 bilateral or grade 
3–4 unilateral) was based on the judgement of two central 
readers. In the event of disagreement, a third reader’s results 
were used to provide a majority. Agreement between central 
readers was calculated using simple kappa (κ) statistics. Statis-
tical analyses were performed with SAS V.9.3 and V.9.4.
results
Patient disposition and baseline characteristics
Three hundred and twenty-five patients were randomised at 
week 0, 107 to placebo and 218 to CZP (111 to CZP 200 mg 
Q2W and 107 to CZP 400 mg Q4W). Of 315 patients (174 AS 
and 141 nr-axSpA) who received ≥1 dose CZP at any point in 
the trial, 199 (63.2%) completed the study to week 204. One 
hundred and fifty-eight patients had valid MRI assessments at 
baseline and ≥1 other timepoint (MRI set). The baseline char-
acteristics of the MRI set and overall population were similar 
(table 1, and data not shown).
One hundred and ninety-six patients had ≥1 mSASSS assess-
ment and were included in the MMRM and multiple imputation 
analyses of radiograph parameters (X-ray set; online supplemen-
tary table 2); this included 45 patients who received 1 mSASSS 
reading at baseline with no further mSASSS assessments during 
the study. No major differences in disease activity were observed 
between those with and without complete mSASSS data 
(online supplementary table 3). One hundred and thirty-seven 
patients with SI joint radiographs at baseline and week 204/early 
withdrawal were assessed for radiographic progression based on 
the mNY criteria.
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MrI data
Spinal and SI joint MRI assessments showed reduction of inflam-
mation with rapid improvements from baseline to week 12 main-
tained to week 204 (figure 1). At baseline, the LS mean spinal 
inflammation assessed by Berlin score (standard error; SE) for 
AS and nr-axSpA subpopulations was 7.4 (0.92) and 4.4 (1.03), 
respectively, which reduced to 2.5 (0.50) and 1.7 (0.40) at week 
12, and 2.6 (0.56) and 1.9 (0.44) at week 204. Similarly, the 
LS mean SPARCC scores for patients with AS and nr-axSpA at 
baseline were 8.5 (1.45) and 7.5 (1.53), respectively, which were 
reduced to 1.6 (0.66) and 2.6 (0.67) at week 12, and were main-
tained at 1.3 (0.46) and 2.4 (0.85) at week 204.
Of patients with respective inflammation at baseline, 66.7% 
(AS) and 69.6% (nr-axSpA) achieved SI joint MRI remission at 
week 204, and 65.4% of patients with AS and 57.3% of patients 
with nr-axSpA achieved spinal MRI remission.
radiographic progression
Limited changes in SI joint grading were observed to week 204: 
2/44 (4.5%) patients with nr-axSpA fulfilled the mNY criteria, 
while 4/93 (4.3%) patients with AS no longer did so at week 
204. Agreement between the two central readers regarding 
the absence/presence of radiographic sacroiliitis was moderate, 
with disagreement occurring in 39/158 cases assessed at base-
line (κ=0.49). In total, 113/158 (71.5%) images were read by 
a third reader due to grading disagreements between the main 
two readers.
Mean baseline mSASSS scores of 13.2 and 4.4 were observed 
in patients with AS and nr-axSpA, respectively. Limited spinal 
radiographic progression occurred in CZP-treated patients, with 
most progression seen in the AS cohort. In patients with AS, 
the mean mSASSS change between baseline and week 204 was 
0.98 (95% CI 0.34 to 1.63), with the majority of progression 
observed during the first 2-year period (0.67 (95% CI 0.21 to 
1.13)) compared with years 2–4 (0.31 (95% CI 0.02 to 0.60); 
figure 2). Patients with nr-axSpA exhibited a mean mSASSS 
change of 0.06 (95% CI −0.17 to 0.28) over 204 weeks. 
Observed changes in patients with complete mSASSS readings 
available at baseline, week 96 and week 204 are summarised 
in online supplementary figure 2; observed mean mSASSS 
changes between baseline and week 204 were 1.12 and 0.04 for 
patients with AS and nr-axSpA, respectively. Patients with AS 
who progressed during years 1 and 2 were more likely to prog-
ress in the second 2-year period: within-patient correlation coef-
ficients between change from baseline to week 96, and change 
from week 96 to week 204, were 0.53 (AS) and 0.05 (nr-axSpA).







Mean age, years (SD) 39.7 (12.0) 41.5 (11.7) 37.5 (11.9)
Male, % 62.2 73.0 48.9
Symptom duration, years, median (min, max) 7.8 (0.3, 50.9) 9.1 (0.3, 50.9) 5.8 (0.3, 41.5)
CRP, mg/L, median (min, max) 13.4 (0.1, 174.8) 14.2 (0.1, 174.8) 12.0 (0.1, 156.2)
Patients with elevated CRP (>15 mg/L), % 40.6 43.7 36.9
BASDAI, mean (SD) 6.4 (1.5) 6.4 (1.6) 6.5 (1.5)
BASFI, mean (SD) 5.4 (2.3)
 n=314
5.7 (2.2) 4.9 (2.3)
 n=140
BASMI linear, mean (SD) 3.8 (1.7) 4.4 (1.7) 3.1 (1.5)
ASDAS, mean (SD) 3.9 (0.9)
 n=313




   Mean (SD)* 9.5 (16.1) 13.2 (18.2) 4.4 (11.0)






  Patients with ≥1 bridging or non-bridging syndesmophyte at baseline, n (%) 63 (33.2) 47 (42.7) 16 (20.0)
MRI set n=158 n=92 n=66
  SPARCC (SI joints)
   Mean (95% CI)* 8.1 (6.1, 10.2) 8.5 (5.6, 11.4) 7.5 (4.4, 10.6)






  Patients with MRI inflammation (SPARCC ≥2), estimate, % 51.2 47.0 57.3
  Berlin score (spine)
   Mean (95% CI)* 6.2 (4.8, 7.5), n=157 7.4 (5.6, 9.2) 4.4 (2.4, 6.5), n=65








*Least squares mean scores were estimated using mixed-model for repeated measures analyses. Inflammation was defined as Berlin >2 or SPARCC ≥2. Data are presented for all 
patients who received ≥1 dose CZP at any point in the trial. To define AS and nr-axSpA subpopulations, the most recent SI joint X-rays (performed ≤12 months prior to screening) 
were locally read to determine the presence/absence of radiographic sacroiliitis. 
AS, ankylosing spondylitis; ASDAS, Ankylosing Spondylitis Disease Activity Score; axSpA, axial spondyloarthritis; BASDAI, Bath Ankylosing Spondylitis Activity Index; BASFI, 
Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; CRP, C-reactive protein; CZP, certolizumab pegol; mSASSS, modified Stoke 
Ankylosing Spondylitis Spine Score; nr, non-radiographic; SI, sacroiliac; SPARCC, Spondyloarthritis Research Consortium of Canada. 
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Based on the multiple imputation analysis, 84.2% of patients 
with AS did not progress (progression was defined as an mSASSS 
increase of ≥2 points) from baseline to week 96. By week 204, 
80.6% of patients with AS had not progressed. Progression was 
observed in only two patients with nr-axSpA, and therefore 
multiple imputation analysis was not performed. Of 85 patients 
with AS, 5 (5.9%) developed ≥1 syndesmophyte by week 96 and 
only 1 patient with nr-axSpA demonstrated one new syndesmo-
phyte during the study. Sixty-one AS patients were assessed at 
week 204; at that time, no additional patients were observed 
to develop syndesmophytes. No patients with an absence of 
syndesmophytes at baseline developed syndesmophytes at 
4 years. Individual patient mSASSS results are presented in 
figure 3.
dIsCussIOn
RAPID-axSpA is the first long-term, large study to investigate 
imaging results in AS and nr-axSpA subpopulations when treated 
with a TNF-inhibitor. Here, CZP treatment rapidly improved 
axSpA inflammation of the spine and SI joints as observed using 
MRI in patients with AS and nr-axSpA. These improvements 
Figure 1 MRI imaging results to week 204. Sustained improvement in (A) LS mean Berlin score (MMRM), (B) percentage of patients in MRI spinal 
remission (Berlin score ≤2) to week 204 (missing at random (MAR)) in the subgroup of patients with MRI spinal inflammation at baseline (Berlin 
score >2), (C) LS mean SPARCC SIJ score (MMRM), and (D) percentage of patients in MRI SIJ remission (SPARCC score <2) to week 204 (MAR) in 
the subgroup of patients with inflammation at baseline (SPARCC ≥2). AS, ankylosing spondylitis; LS, least squares; MMRM, mixed-model repeated 
measures; nr-axSpA, non-radiographic axial spondyloarthritis; SIJ, sacroiliac joints; SPARCC, Spondyloarthritis Research Consortium of Canada. 
Figure 2 Radiographic imaging results of the spine to week 204. AS, ankylosing spondylitis; LS, least squares; mSASSS, modified Stoke Ankylosing 
Spondylitis Spine Score; nr-axSpA, non-radiographic axial spondyloarthritis. 
 on 6 A









is: first published as 10.1136/annrheum




703van der Heijde D, et al. Ann Rheum Dis 2018;77:699–705. doi:10.1136/annrheumdis-2017-212377
Clinical and epidemiological research
were maintained to week 204, with similar responses observed 
in both populations.
Changes from baseline in Berlin spine and SPARCC SI joint 
scores were comparable with other AS and nr-axSpA trials.16 17 
However, none of the longer term MRI studies (spanning up 
to 3 years of therapy) have reported results of both patients 
with AS and nr-axSpA in parallel.16 18–21 It is important to note 
that comparisons between clinical trials should be treated with 
caution, as differences in population, study design and the years 
in which the trial was conducted can lead to variation between 
study outcomes. Comparisons between trials commencing at 
largely different timepoints may introduce chronology bias 
caused by differences in standard medical practice at the time of 
each investigation.
Many patients with MRI inflammation at baseline achieved 
spinal and SI joint MRI remission by week 204, with improve-
ments in both scores seen as early as week 12 in both AS and 
nr-axSpA cohorts. Spinal MRI inflammation has been shown to 
be associated with radiographic progression, as vertebral edge 
inflammation contributes to the development of new syndesmo-
phytes, although it remains to be proven that by reducing MRI 
inflammation in early axSpA, future structural damage may be 
prevented.
Limited changes from mNY negative to mNY positive were 
observed. Net progression to week 204 was minimal (−1.5%); 
similar proportions of patients ‘progressed’ from nr-axSpA to 
AS (4.5%) as ‘regressed’ from AS to nr-axSpA (4.3%). Given 
the low numbers of patients whose disease was reclassified, and 
the similar movement in both directions between the two popu-
lations, this is likely to represent intrareader variability, with 
little true progression. Previous follow-ups of untreated axSpA 
cohorts have reported progression rates (from nr-axSpA to AS) 
between 10% and 12% over 2 years.22–24 In the DEvenir des 
Spondyloarthrites Indifférenciées Récentes (DESIR) cohort, 
the net progression from nr-axSpA to radiographic axSpA 
(AS) was 5.1% over 5 years.25 However, a direct compar-
ison between DESIR and RAPID-axSpA is not recommended 
since DESIR was a prevalence cohort of early axSpA. RAPID-
axSpA also included patients with longer disease duration and 
higher disease activity. During the ESTHER trial, radiographic 
progression from nr-axSpA to AS was observed mainly between 
baseline and year 2 with no patients progressing to AS between 
years 2 and 4. In EMBARK, in which 161 patients had X-rays 
available at baseline and week 104, one patient (0.6%) satis-
fied the mNY criteria at baseline. Of 160 patients with mNY 
negative scores at baseline, none became mNY positive at week 
104.19 26
Recognition of sacroiliitis on pelvic radiographs is gener-
ally considered to be difficult, due to both the complexity of 
the SI joints and the poor visualisation associated with plain 
radiographs. Previous radiographic studies have observed large 
intraobserver/interobserver variability in reading SI joint radio-
graphs,27–29 with significant variability reported between central 
and local readers.22 In RAPID-axSpA, determination of mNY 
status, used as a stratification factor, was based on local SI X-ray 
reads, which are more reflective of daily clinical practice. This 
approach has been used in a number of previous AS trials investi-
gating anti-TNFs, as well as the ABILITY-1 nr-axSpA study.
The rates of spinal radiographic progression in patients with 
axSpA are variable2; however, in the majority of patients with 
axSpA, several years may elapse before new bone formation 
in radiographs can be assessed. Therefore, a minimum 2-year 
follow-up is required to investigate radiographic progression. 
Structural spinal damage and inflammation in axSpA have an 
impact on patient quality of life, especially through reduction 
of mobility and function.30–32 Recently Poddubnyy et al33 inves-
tigated the effect of radiographic spinal progression and disease 
activity on function and spinal mobility in anti-TNF-treated 
patients with established AS. Both functional status and spinal 
mobility remained stable during 10 years of anti-TNF therapy 
despite radiographic progression, suggesting that reduction and 
control of inflammation may counteract the effects of radio-
graphic spinal progression at a group level.
Interestingly, no patients with an absence of syndesmophytes 
at baseline developed syndesmophytes during 4 years of CZP 
treatment. Several studies showed that syndesmophyte preva-
lence predisposes to more rapid radiographic progression, and 
therefore could be used as a predictor for future radiographic 
damage despite the variability of progression rates in patients 
with axSpA.34–36
Figure 3 Proportion of patients with spinal progression at years 2 and 4. AS, ankylosing spondylitis; CFB, change from baseline; mSASSS, modified 
Stoke Ankylosing Spondylitis Spine Score; nr-axSpA, non-radiographic axial spondyloarthritis.  
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Here, we observed limited spinal radiographic progres-
sion, with a decrease in progression rate with long-term CZP 
therapy. After 4 years, 80.6% of patients with AS did not prog-
ress (<2 mSASSS points change from baseline) and the mean 
change was 0.98. As expected, patients with AS in RAPID-axSpA 
were generally more progressive than patients with nr-axSpA. 
The limited progression over 4 years observed in this study in 
patients with AS (80.3% non-progression defined as mSASSS 
change from baseline <2) is consistent with recent reports 
from the MEASURE 1 trial, in which 79% of patients with AS 
treated with secukinumab did not progress (<2 mSASSS points 
change from baseline) over 4 years.37 However, these findings 
cannot be used in isolation to confirm an impact on disease 
progression since in both cases a control was absent. In the 
absence of a control arm, further data are required to eluci-
date the natural history of AS to better understand the impact 
of biologic treatment on disease progression. Long-term spinal 
X-ray data have also been reported for patients with AS in the 
GO-RAISE study38 (4 years) and in an 8-year follow-up to a 
randomised controlled trial investigating the effects of inflix-
imab, although this was conducted using a limited number of 
patients (n=69).39 In GO-RAISE, patients with AS treated with 
50 mg or 100 mg golimumab every 4 weeks demonstrated a 
mean mSASSS change from baseline (SD) of 1.3 (4.1) and 2.0 
(5.6), respectively, at week 20838 (although it should be noted 
that the GO-RAISE study should not be directly compared 
with RAPID-axSpA due to differing trial designs and study 
populations).
Two-year radiographic results from RAPID-axSpA exhibited 
a mean mSASSS change of 0.67 observed in patients with AS to 
week 96. The decrease in progression rate observed in RAPID-
axSpA between years 2 and 4, and the diminished progression 
observed in long-term anti-TNF studies,40 41 support earlier 
observations that prolonged use of TNF inhibitors may be asso-
ciated with reduction of progression. Further evidence suggests 
a link between disease activity and radiographic progression. 
Results from the OASIS study, in which patients with AS were 
followed up for 12 years, found that disease activity was longi-
tudinally associated with radiographic progression. In an AS 
prospective cohort study, the observed reduction in radiographic 
progression during anti-TNF treatment appeared to be medi-
ated by a decrease in disease activity.42 Consequently, long-term 
anti-TNF treatment could have the potential to inhibit structural 
progression by suppressing disease activity.
The analyses reported here are not without limitation. Patient 
withdrawal introduces bias, since patients whose symptoms do 
not improve sufficiently or those who suffer side effects are less 
likely to continue the trial. In long-term studies, the cumulative 
impact of missing data is more pronounced. Notably, there was 
a high proportion of missing MRI and radiographic data in this 
study. Since disease activity is likely to be associated with radio-
graphic progression, ASDAS outcomes were compared between 
those with and without complete mSASSS assessments. Given 
that no major differences were observed, it is unlikely that study 
dropouts or otherwise missed assessments would have caused 
major bias to the study results.
Use of the mSASSS scoring system for quantification of 
radiographic progression could also be considered a limitation. 
The mSASSS system captures changes at the anterior vertebral 
corners of both the cervical and lumbar spine,5 but does not 
evaluate other elements of the axial skeleton, for example, the 
thoracic spine or facet joints.43 Subsequently, changes in these 
regions may have gone undetected. Nevertheless, at present, the 
mSASSS is the preferred scoring method for use in AS and is 
endorsed by the ASAS and Outcome Measures in Rheumatology 
(OMERACT).44
As two readers were used to evaluate the presence and forma-
tion of syndesmophytes, it was important to establish the level 
of agreement required. Here, agreement between readers was 
required at vertebral edge level; this approach is likely to under-
estimate the prevalence and incidence of syndesmophytes, but 
has been used in previous trials such as the ASSERT study.32
In conclusion, early improvements in MRI inflammation 
observed in a CZP-treated axSpA population, including both 
patients with AS and nr-axSpA, were maintained to week 204. 
MRI assessments demonstrated a rapid reduction of inflamma-
tion and sustained rates of remission in both SI joint and spinal 
examinations. Radiograph assessments revealed a low rate of 
spinal progression during the first 2 years of RAPID-axSpA with 
a decrease in the rate of spinal progression observed between 
years 2 and 4, and limited SI joint progression during 4 years 
of study.
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